Gentherm is expected to report a year-over-year earnings decline of 6.9% to $0.68 per share for Q3 2026, despite revenue growth of 4.5% to $404.18 million. With a negative Earnings ESP of -5.61% and Zacks Rank #3, the stock is not considered a compelling earnings-beat candidate. However, the company has beaten consensus estimates in 3 of the last 4 quarters, most recently delivering a +27.12% surprise.

In a comparison of two automotive stocks, Gentherm (THRM) emerges as the superior value opportunity compared to Ferrari (RACE). THRM holds a Zacks Rank #1 (Strong Buy) with a Value grade of A, supported by a forward P/E of 13.29 and PEG ratio of 0.89. RACE, rated #3 (Hold) with a Value grade of D, has a forward P/E of 36.85 and PEG ratio of 3.54, indicating significantly higher valuations.

Gentherm shareholders voted to approve the proposed combination with Modine's Performance Technologies business, with approximately 99% voting in favor of share issuance and 94% supporting charter amendments. The transaction has received all required regulatory approvals and is expected to close on October 1, 2026. The combined entity aims to create a higher-growth, higher-margin thermal and precision flow management business.

Gentherm announced the acquisition of Innovative Medical Equipment, LLC (IME), a Cleveland-based provider of the ThermaZone® thermal therapy device. The acquisition expands Gentherm's medical product portfolio and customer base in healthcare, supporting the company's strategy to leverage its thermal management expertise into new markets. The deal is expected to deliver revenue synergies through expanded customer relationships and channels.

Gentherm announced FDA 510(k) clearance for its ThermAffyx Patient Safety System, a patented integrated device combining active patient warming, securement, and pressure reduction for robotic-assisted surgical procedures. Product trials begin in August with revenue expected in Q3 2026. The device addresses a critical gap where over 25% of robotic surgery patients experience hypothermia despite current warming interventions.

Gentherm announced it will report its second quarter 2026 financial results on July 23, 2026, followed by a conference call at 8 am ET. The company, a global leader in thermal management and pneumatic comfort technologies, will discuss results with investors via phone and webcast. A replay will be available for one year.

Gentherm, a thermal management technology leader, is expanding its automotive innovations into home and office furniture markets. The company will showcase its WellSense technology at NeoCon 2026, featuring integrated thermal and pneumatic systems for wellness recliners, office chairs, smart desks, and medical seating. The expansion is backed by extensive human physiology research, including 7,000+ hours of human testing and 19 completed clinical studies.

Harvey Partners purchased 431,072 shares of Gentherm in Q3, increasing its stake to approximately 1 million shares valued at $34.9 million. Despite the stock being down 13% over the past year, the company reported record quarterly revenue and strong operational performance.

Gentherm reported Q2 2025 financial results with revenue of $375.1 million, slightly below previous year. Despite securing $620 million in new automotive business awards, the company experienced margin compression and reduced net income due to higher costs and currency fluctuations.

Gentherm reported Q2 2025 revenues of $375 million, secured $620 million in automotive new business awards, and maintained a measured approach amid macro uncertainties. Gross margin decreased and net income dropped compared to the previous year.

Gentherm has extended its partnership with DUOMED to offer patient temperature management technologies in France and Benelux, including Astopad® and Vytil-branded warming systems.

Gentherm announced that it has granted inducement equity awards to its newly appointed CEO and CFO, consisting of restricted stock units that vest over three years. The awards were made in accordance with the previously announced offer letters and were approved by the Compensation and Talent Committee under the Nasdaq employment inducement exemption.